Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s).

Clifford DB, Evans S, Yang Y, Acosta EP, Ribaudo H, Gulick RM; A5097s Study Team.

HIV Clin Trials. 2009 Nov-Dec;10(6):343-55. doi: 10.1310/hct1006-343.

2.

[Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].

Domingo P, Ribera E.

Enferm Infecc Microbiol Clin. 2013 Jun;31 Suppl 2:20-9. doi: 10.1016/S0213-005X(13)70139-3. Review. Spanish.

PMID:
24252530
3.

Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis.

Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, Renaud-Théry F, Shaffer N, Hargreaves S, Mills EJ, Ford N.

AIDS. 2013 Jun 1;27(9):1403-12. doi: 10.1097/QAD.0b013e32835f1db0. Review.

PMID:
23343913
4.

WITHDRAWN: Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV.

Omeje I, Okwundu CI.

Cochrane Database Syst Rev. 2012 May 16;(5):CD007276. doi: 10.1002/14651858.CD007276.pub3. Review.

PMID:
22592718
5.

WITHDRAWN. Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV.

Omeje I, Okwundu CI.

Cochrane Database Syst Rev. 2012 Feb 15;(2):CD007276. doi: 10.1002/14651858.CD007276.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;(5):CD007276.

PMID:
22336829

Supplemental Content

Support Center